Fig. 3: Probabillities of reachievement of molecular remission after loss of MMR. | Leukemia

Fig. 3: Probabillities of reachievement of molecular remission after loss of MMR.

From: Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

Fig. 3

Left panel: Median time to reachievement of MMR was 3.1 months in the ropeg-IFN group vs. 3.2 months in the placebo group. Right panel: Median time to MR [4] was 4.2 months in the ropeg-IFN group vs. 4.8. months in the placebo group. MMR, major molecular remission; MR [4], molecular remission BCR::ABL ≤ 0.01% according to international scale; TKI tyrosine kinase inhibitor.

Back to article page